Peer-Reviewed Research
Ipamorelin is a selective growth hormone secretagogue and agonist of the ghrelin/growth hormone secretagogue receptor. Published studies have examined its effects on growth hormone release, pharmacokinetics, gastrointestinal motility, bone formation, and muscle function. Direct modern Ipamorelin research is limited, so the strongest available evidence includes foundational human and preclinical studies alongside recent scientific reviews.
Human Clinical Research
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers
Journal: Pharmaceutical Research
Published: 1999
Study Type: Randomized dose-escalation human clinical trial
Summary
This study evaluated Ipamorelin’s pharmacokinetics and growth-hormone response in healthy male volunteers across five intravenous infusion levels. Researchers reported dose-proportional pharmacokinetics, an approximately two-hour terminal half-life, and a single episode of growth-hormone release following administration.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/10496658/
DOI:
https://doi.org/10.1023/A:1018955126402
Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients
Journal: International Journal of Colorectal Disease
Published: 2014
Study Type: Phase 2 randomized, controlled human clinical trial
Summary
This proof-of-concept trial evaluated Ipamorelin for postoperative ileus following bowel-resection surgery. The study assessed gastrointestinal recovery, safety, and clinical outcomes. Ipamorelin did not produce a statistically significant improvement in the primary efficacy endpoint, making this an important example of human findings that were less favorable than earlier preclinical results.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/25331030/
Foundational Original Research
Ipamorelin, the first selective growth hormone secretagogue
Journal: European Journal of Endocrinology
Published: 1998
Study Type: Original pharmacology research
Summary
This foundational study characterized Ipamorelin as a selective growth hormone secretagogue. In experimental models, Ipamorelin stimulated growth-hormone release while producing substantially less activation of ACTH and cortisol than several earlier growth hormone-releasing peptides.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/9849822/
Read Publication:
https://doi.org/10.1530/eje.0.1390552
Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus
Journal: Journal of Pharmacology and Experimental Therapeutics
Published: 2009
Study Type: Original preclinical animal research
Summary
Researchers investigated whether Ipamorelin could improve gastrointestinal transit in a rodent model of postoperative ileus. Treatment accelerated gastric emptying and intestinal transit and reduced several features associated with postoperative gastrointestinal dysfunction. These preclinical findings helped support the later human trial.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/19289567/
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation rate of adult rats
Journal: Growth Hormone & IGF Research
Published: 2001
Study Type: Original preclinical animal research
Summary
This study evaluated Ipamorelin in rats receiving glucocorticoids. Ipamorelin was associated with increased periosteal bone-formation rates and improved maximum muscle tension compared with glucocorticoid treatment alone. The findings were obtained in an animal model and do not establish equivalent effects in humans.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/11735244/
DOI:
https://doi.org/10.1054/ghir.2001.0239
Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues in rats
Journal: Xenobiotica
Published: 1998
Study Type: Original preclinical pharmacokinetic research
Summary
Researchers compared the pharmacokinetics of Ipamorelin with several other peptide growth hormone secretagogues following different administration routes in rats. Ipamorelin demonstrated lower systemic clearance than GHRP-6 and distinct pharmacokinetic characteristics compared with the other compounds studied.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/9879640/
Recent Review Articles
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
Published: 2026
Study Type: Scientific and clinical review
Summary
This review examines injectable peptides promoted in orthopedic and sports-medicine settings, including Ipamorelin and related growth hormone secretagogues. It discusses proposed mechanisms, preclinical findings, limited human evidence, safety concerns, product quality, and the need for stronger controlled clinical research.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/41476424/
Injectable Peptides in Sports Medicine: A Structured Narrative Review
Published: 2026
Study Type: Structured narrative review
Summary
This review evaluates contemporary human and translational evidence for injectable peptides used in musculoskeletal recovery and performance-related settings. The authors emphasize that clinical use has advanced faster than the supporting evidence and distinguish mechanistic or preclinical findings from established human outcomes.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/42160466/
The Safety and Efficacy of Growth Hormone Secretagogues
Journal: Sexual Medicine Reviews
Published: 2018
Study Type: Scientific review
Summary
This review summarizes research on growth hormone secretagogues as a class, including their effects on pulsatile growth-hormone secretion, body composition, appetite, bone biology, and potential clinical applications. It also notes the shortage of long-term, rigorously controlled safety and efficacy studies. This is class-level evidence rather than an Ipamorelin-specific clinical trial.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/28400207/
Additional Ipamorelin Publications
Browse current PubMed research:
https://pubmed.ncbi.nlm.nih.gov/?term=ipamorelin
Research Disclaimer
The information presented in this Research Library is provided for educational and scientific reference purposes only and is based on published peer-reviewed research. Research findings continue to evolve, and investigational compounds may not be approved for clinical use. All Pearland Peptides products are supplied For Research Use Only and are not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease.